In-house discovered and In-licensed projects（As of May 12, 2025）
| Development Code | Planned Indication | Development Stage | Remarks |
|---|---|---|---|
| KAR | Head lice | Phase Ⅲ | In-licensed from Arbor Pharmaceuticals, LLC. Product name in the US: Sklice |
| KP-001 | Refractory vascular malformations | Phase Ⅲ | In-house discovered product |
| KC-8025 (Seladelpar) | Primary biliary cholangitis | Phase Ⅲ | In-licensed from CymaBay Therapeutics, Inc. Acquired by Gilead Sciences in February 2024. |
| ESK-001 | Plaque psoriasis | Phase Ⅲ | In-licensed from Alumis Inc. Under global Phase Ⅲ (incl. Japan) |
| KP-483 | Solid tumors (immuno-oncology) |
Phase Ⅰ | In-house discovered product |
| KP-910 | Peripheral neuropathic pain | Phase Ⅰ | In-house discovered product |
| Tildacerfont | Congenital adrenal hyperplasia | Phase Ⅰ | In-licensed from Spruce Biosciences, Inc. |
| KP-001(USA) | Refractory vascular malformations | Phase Ⅰ | In-house discovered product Consulting with FDA on Phase Ⅲ plan |
Note:Kaken will advance KP-723, an oral STAT6 inhibitor in preclinical development, to the completion of Phase Ⅰ clinical trials, which had entered into a licence agreement with J&J.
Other（As of May 12, 2025）
| Development Code | Planned Indication | Development Stage | Remarks |
|---|---|---|---|
| Sebetralstat | Hereditary Angioedema | Authorization application | Applied by KalVista Pharmaceuticals |
| NM-26 | Atopic dermatitis | Phase Ⅱ | Clinical trial underway after IP transfer to J&J |
Note:The medical device "Silk-Elastin Wound Healing Sheet", for which a marketing authorization application had been submitted by the licensor, Sanyo Chemical Industries, Ltd., was approved on April 21, 2025.
Status of Out-Licensed Products Overseas
（As of May 12, 2025）
| Generic name (domestic sales name) |
Planned Indication | Development Stage | Out-licensed(Developing country) |
|---|---|---|---|
| Efinaconazole (Clenafin) |
Onychomycosis | Authorization application | Almirall S.A.(Germany ※Italy:Approved Mar 2025) |
| Efinaconazole (Clenafin) |
Onychomycosis | Phase Ⅲ | AIM(China) |
| Sofpironium bromide (Ecclock) |
Primary axillary hyperhidrosis | Authorization application | Dong-Wha Pharm Co., Ltd.(Korea) |